D.E. Shaw & Co
CAI

D.E. Shaw & Co’s Caris Life Sciences CAI Stock Holding History

D.E. Shaw & Co’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.65M Buy
204,818
+75,241
+58% +$1.35M ﹤0.01% 2673
2026
Q1 		$2.32M Buy
+129,577
New +$2.83M ﹤0.01% 2804
2025
Q4 		– Sell
-49,785
Closed -$1.51M – 5119
2025
Q3 		$1.51M Buy
49,785
+42,285
+564% +$1.35M ﹤0.01% 3183
2025
Q2 		$200K Buy
+7,500
New +$202K ﹤0.01% 4052

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
SSP
Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co's CAI Position: Q2 2026 in Review

D.E. Shaw & Co increased its Caris Life Sciences (CAI) stake by 58% in Q2 2026, buying an estimated $1.35M and bringing the position to 204,818 shares worth $3.65M. The position accounts for ﹤0.01% of the portfolio, ranked #2673.

D.E. Shaw & Co first reported a position in CAI in Q2 2025 and has held it in 4 quarters since. 247 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

  • D.E. Shaw & Co held 204,818 shares of Caris Life Sciences worth $3.65M as of Q2 2026.
  • D.E. Shaw & Co bought 75,241 Caris Life Sciences shares in Q2 2026, an estimated $1.35M.
  • Caris Life Sciences made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #2673 holding.
  • D.E. Shaw & Co first reported a position in Caris Life Sciences in Q2 2025 and has held it in 4 quarters since.
  • 247 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.